Literature DB >> 30996803

Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition.

Assunta Giordano1,2, Giovanni Forte2, Stefania Terracciano2, Alessandra Russo2, Marina Sala2, Maria C Scala2, Catrine Johansson3, Udo Oppermann3, Raffaele Riccio2, Ines Bruno2, Simone Di Micco2.   

Abstract

JMJD3 is a member of the KDM6 subfamily and catalyzes the demethylation of lysine 27 on histone H3 (H3K27). This protein was identified as a useful tool in understanding the role of epigenetics in inflammatory conditions and in cancer as well. Guided by a virtual fragment screening approach, we identified the benzoxazole scaffold as a new hit suitable for the development of tighter JMJD3 inhibitors. Compounds were synthesized by a microwave-assisted one-pot reaction under catalyst and solvent-free conditions. Among these, compound 8 presented the highest inhibitory activity (IC50 = 1.22 ± 0.22 μM) in accordance with molecular modeling calculations. Moreover, 8 induced the cycle arrest in S-phase on A375 melanoma cells.

Entities:  

Year:  2019        PMID: 30996803      PMCID: PMC6466828          DOI: 10.1021/acsmedchemlett.8b00589

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

1.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

2.  Identifying chelators for metalloprotein inhibitors using a fragment-based approach.

Authors:  Jennifer A Jacobsen; Jessica L Fullagar; Melissa T Miller; Seth M Cohen
Journal:  J Med Chem       Date:  2010-12-28       Impact factor: 7.446

3.  JMJD3 is a histone H3K27 demethylase.

Authors:  Yang Xiang; Ziqi Zhu; Gang Han; Hanqing Lin; Longyong Xu; Charlie Degui Chen
Journal:  Cell Res       Date:  2007-10       Impact factor: 25.617

4.  The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma.

Authors:  J A Anderton; S Bose; M Vockerodt; K Vrzalikova; W Wei; M Kuo; K Helin; J Christensen; M Rowe; P G Murray; C B Woodman
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

5.  The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing.

Authors:  Francesca De Santa; Maria Grazia Totaro; Elena Prosperini; Samuele Notarbartolo; Giuseppe Testa; Gioacchino Natoli
Journal:  Cell       Date:  2007-09-06       Impact factor: 41.582

6.  Chelator fragment libraries for targeting metalloproteinases.

Authors:  Arpita Agrawal; Sherida L Johnson; Jennifer A Jacobsen; Melissa T Miller; Li-Hsing Chen; Maurizio Pellecchia; Seth M Cohen
Journal:  ChemMedChem       Date:  2010-02-01       Impact factor: 3.466

7.  Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS.

Authors:  Marta Barradas; Emma Anderton; Juan Carlos Acosta; Side Li; Ana Banito; Marc Rodriguez-Niedenführ; Goedele Maertens; Michaela Banck; Ming-Ming Zhou; Martin J Walsh; Gordon Peters; Jesús Gil
Journal:  Genes Dev       Date:  2009-05-15       Impact factor: 11.361

8.  Ku affects the ATM-dependent S phase checkpoint following ionizing radiation.

Authors:  Xiang-Yang Zhou; Xiang Wang; Hongyan Wang; David J Chen; Gloria C Li; George Iliakis; Ya Wang
Journal:  Oncogene       Date:  2002-09-12       Impact factor: 9.867

9.  Jmjd3 contributes to the control of gene expression in LPS-activated macrophages.

Authors:  Francesca De Santa; Vipin Narang; Zhei Hwee Yap; Betsabeh Khoramian Tusi; Thomas Burgold; Liv Austenaa; Gabriele Bucci; Marieta Caganova; Samuele Notarbartolo; Stefano Casola; Giuseppe Testa; Wing-Kin Sung; Chia-Lin Wei; Gioacchino Natoli
Journal:  EMBO J       Date:  2009-09-24       Impact factor: 11.598

10.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Authors:  Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

View more
  4 in total

Review 1.  Emerging roles of JMJD3 in cancer.

Authors:  Maryam Farzaneh; Zeinab Kuchaki; Fatima Rashid Sheykhahmad; Seyed Mohammadmahdi Meybodi; Yusef Abbasi; Effat Gholami; Farhoodeh Ghaedrahmati; Omid Anbiyaee
Journal:  Clin Transl Oncol       Date:  2022-03-03       Impact factor: 3.405

Review 2.  The Functions of the Demethylase JMJD3 in Cancer.

Authors:  Anna Sanchez; Fatma Zohra Houfaf Khoufaf; Mouhamed Idrissou; Frédérique Penault-Llorca; Yves-Jean Bignon; Laurent Guy; Dominique Bernard-Gallon
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

3.  In silico Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate.

Authors:  Simone Di Micco; Simona Musella; Maria C Scala; Marina Sala; Pietro Campiglia; Giuseppe Bifulco; Alessio Fasano
Journal:  Front Chem       Date:  2021-01-15       Impact factor: 5.221

4.  Biological activity of 3-(2-benzoxazol-5-yl)alanine derivatives.

Authors:  Katarzyna Guzow; Ewa Mulkiewicz; Michał Obuchowski; Wiesław Wiczk
Journal:  Amino Acids       Date:  2021-07-08       Impact factor: 3.520

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.